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ING116070: A Study of the Pharmacokinetics
and Antiviral Activity of Dolutegravir in
Cerebrospinal Fluid in HIV-1–Infected,
Antiretroviral Therapy–Naive Subjects
Scott L. Letendre,1 Anthony M. Mills,2 Karen T. Tashima,3 Deborah A. Thomas,4 Sherene S. Min,4 Shuguang Chen,4
Ivy H. Song,4 and Stephen C. Piscitelli4; on behalf of the extended ING116070 study team
1University of California, San Diego, and 2Anthony Mills, MD, Inc, Los Angeles, California; 3The Miriam Hospital, Providence, Rhode Island; and
4GlaxoSmithKline, Durham, North Carolina
Background. Dolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase in-
hibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF).
Methods. ING116070 is an ongoing, single-arm, open-label, multicenter study in antiretroviral therapy–naive,
HIV-1–infected adults. Subjects received DTG (50 mg) plus abacavir/lamivudine (600/300 mg) once daily. The CSF
and plasma (total and unbound) DTG concentrations were measured at weeks 2 and 16. The HIV-1 RNA levels were
measured in CSF at baseline and weeks 2 and 16 and in plasma at baseline and weeks 2, 4, 8, 12, and 16.
Results. Thirteen white men enrolled in the study; 2 withdrew prematurely, 1 because of a non–drug-related
serious adverse event (pharyngitis) and 1 because of lack of treatment efficacy. The median DTG concentrations
in CSF were 18 ng/mL (range, 4–23 ng/mL) at week 2 and 13 ng/mL (4–18 ng/mL) at week 16. Ratios of DTG
CSF to total plasma concentration were similar to the unbound fraction of DTG in plasma. Median changes
from baseline in CSF (n = 11) and plasma (n = 12) HIV-1 RNAwere −3.42 and −3.04 log10 copies/mL, respectively.
Nine of 11 subjects (82%) had plasma and CSF HIV-1 RNA levels <50 copies/mL and 10 of 11 (91%) had CSF HIV-1
RNA levels <2 copies/mL at week 16.
Conclusions. The DTG concentrations in CSF were similar to unbound plasma concentrations and exceeded the
in vitro 50% inhibitory concentration for wild-type HIV (0.2 ng/mL), suggesting that DTG achieves therapeutic con-
centrations in the central nervous system. The HIV-1 RNA reductions were similar in CSF and plasma.
Clinical Trials Registration. NCT01499199.
Keywords. cerebrospinal fluid; dolutegravir; HIV.
Despite the advent of modern, potent antiretroviral
therapy (ART), human immunodeficiency virus (HIV)–
associated neurocognitive impairment continues to be
clinically significant [1–3]. In HIV-infected patients re-
ceiving therapy, HIV has been found in the cerebrospi-
nal fluid (CSF) of individuals who have an undetectable
plasma viral load, both for patients with neurologic
symptoms [4] and for those who are neurologically
asymptomatic [5]. Such discordant findings between
plasma and CSF may be influenced by choice of thera-
py, because treatment with ART that has better estimat-
ed distribution into the central nervous system (CNS)
has been associated with better viral suppression in
CSF [6–8]. Thus, it has become increasingly important
to understand to what degree components of ART can
exert activity within the brain, a long-considered “sanc-
tuary” site [6, 9–11].
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Although the CSF space is not equivalent to the brain extracel-
lular or intracellular environment, drug distribution into the CSF
is a practical way to gain some understanding of the potential for
CNS tissue distribution. Therefore, CSF provides a valuable sur-
rogate to estimate drug distribution and antiviral effects across
the blood-brain barrier and blood-CSF barrier [12–14]. The
CSF distribution of many antiretrovirals, including lopinavir,
darunavir, efavirenz and raltegravir, has been assessed [15–18].
Dolutegravir (DTG; Tivicay, ViiV Healthcare, Research Tri-
angle Park, North Carolina) is a novel HIV integrase inhibitor
(INI) with a pharmacokinetic profile that allows once-daily
administration in INI-naive subjects. The efficacy and safety
of DTG in large, phase III trials have been reported elsewhere
[19, 20]. Dolutegravir is approximately 99% bound to plasma
proteins and is primarily metabolized via uridine 5′-diphospho-
glucuronosyltransferase 1A1, with cytochrome P450 3A4 as a
minor pathway. It is also a substrate of P-glycoprotein and
breast cancer resistance protein. These attributes indicate that
distribution across the blood-brain barrier and blood-CSF bar-
rier will be limited. However, owing to the potency of DTG,
even modest distribution into the CNS may result in concentra-
tions that provide antiviral activity.
Study ING116070 was designed to assess the extent of DTG
entry into the CSF compartment, and to evaluate virologic re-
sponses in CSF and plasma. Results from the planned week 16
primary analysis are presented.
METHODS
Design and Study Population
ING116070 is an ongoing, 96-week, phase IIIb, single-arm,
open-label, multicenter (3 US sites) study in ART-naive (≤10
days of prior therapy), HIV-1–infected adults (≥18 years old).
Eligible participants had a screening plasma HIV-1 RNA level
≥5000 copies/mL and a CD4+ cell count ≥200 cells/mm3 and
were negative for the HLA-B*5701 allele. Exclusions included
contraindication to lumbar puncture, moderate or severe cogni-
tive impairment, evidence of primary viral resistance, active US
Centers for Disease Control and Prevention category C disease
(except Kaposi sarcoma), defined laboratory values, pregnancy,
breastfeeding, moderate or severe hepatic impairment, hepatitis
B virus infection, anticipated need for hepatitis C virus therapy
during the study period, malignancy, or recent treatment with
HIV-1 vaccines or immunomodulators. Ethics committee ap-
proval was obtained at all participating centers in accordance
with the principles of the 2008 Declaration of Helsinki. Each
patient provided written informed consent before undergoing
study procedures. This study is registered at ClinicalTrials.gov
(NCT01499199).
Eligible subjects received (DTG 50 mg) along with the dual
nucleoside reverse-transcriptase inhibitor (NRTI) combination
tablet abacavir/lamivudine (ABC/3TC [Kivexa/Epzicom, ViiV
Healthcare]; 600/300 mg), all taken once daily. The intention-
to-treat exposed and safety populations both comprised all ran-
domized subjects who received ≥1 dose of study medication.
Study End Points
The primary study analyses occurred at week 16; additional
analyses were preplanned for weeks 2 and 96. The primary
end point was the DTG concentration in CSF at week 16. Sec-
ondary end points included DTG concentrations in plasma
(total and unbound) and CSF (total), the relationship between
DTG concentrations in plasma and CSF, the proportion of sub-
jects with plasma HIV-1 RNA <50 or <400 copies/mL, change
from baseline in plasma and CSF HIV-1 RNA, the relationship
between DTG concentration in CSF and HIV-1 RNA in CSF,
and the relationship between plasma and CSF HIV-1 RNA sup-
pression and HIV disease progression and safety parameters (ie,
adverse events [AEs] and laboratory abnormalities). Addition-
ally, the incidence of treatment-emergent genotypic and pheno-
typic resistance to DTG and other on-study ART was assessed
for any subject with protocol-defined virologic failure (PDVF).
Procedures and Assessments
Study visits occurred at baseline and weeks 2, 4, 8, 12, and 16;
additional visits for this ongoing study were scheduled for
weeks 24, 36, and 48, and every 12 weeks thereafter until week
96. Plasma samples were collected at each visit to evaluate
HIV-1 RNA levels (all visits) and plasma DTG concentrations
(weeks 2 and 16; plasma pharmacokinetic samples were collected
2–6 hours after the dose). The CSF samples were obtained by
lumbar puncture at baseline and weeks 2 and 16 for evaluation
of HIV-1 RNA levels and at weeks 2 and 16 for evaluation of
CSF DTG concentrations (collected 2–6 hours after the dose
and within 1 hour of the plasma pharmacokinetic sample). The
CD4+ cell counts were determined at each visit (except week 2).
Central laboratory facilities (Quest Diagnostics) provided he-
matologic, clinical chemistry, and HIV-1 RNA testing. The CSF
HIV-1 RNA levels were determined using an HIV-1 RNA
SuperLow assay (testing provided by bioMONTR Labs) with a
lower limit of detection of 2 copies/mL. First, 2 mL of plasma
was lysed and extracted on the EasyMAG platform (bio-
Mérieux). Eluates containing HIV-1 RNA were aliquoted and
amplified by 3 enzymes: T7 RNA polymerase, Avian myeloblas-
tosis virus reverse transcriptase, and RNase H. Primers and mo-
lecular beacons targeting the pol/gag region of HIV-1 RNA were
used for amplification and detection by isothermal reactions at
41°C. Quantitation of HIV-1 RNA was determined by a propri-
etary reduction algorithm in conjunction with the NucliSENS
EasyQ HIV-1 v2.0 Director software (bioMérieux). Plasma
HIV-1 RNA levels were determined using the RealTime HIV-1
HIV/AIDS • CID 2014:59 (1 October) • 1033
PCR assay (Abbott Molecular); the plasma lower limit of detec-
tion was 40 copies/mL.
Measurements of DTG concentrations were performed using
validated analytic methods based on protein precipitation, fol-
lowed by high-performance liquid chromatography tandem
mass spectrometry analysis [21]. The DTG concentrations in plas-
ma were analyzed by GlaxoSmithKline, and the CSF samples were
analyzed by QPS (Newark, Delaware). For total plasma concentra-
tion, the DTG lower limit of quantification was 20 ng/mL, and the
upper limit was 20 000 ng/mL. Unbound plasma DTG concentra-
tion and total CSF DTG concentrations both had a lower limit of
quantification of 1 ng/mL and an upper limit of 1000 ng/mL.
Safety was assessed throughout the study period, with mon-
itoring and recording of all AEs, serious AEs (SAEs), vital signs,
and laboratory parameters (eg, hematologic, fasting lipid pro-
file, and chemistry results). The AEs were assessed and graded
according to the Division of AIDS toxicity scales [22]. Liver
chemistry threshold stopping criteria were implemented to en-
sure subject safety and to evaluate causes of liver inflammation.
Protocol-defined virologic failure was defined as 2 consecu-
tive plasma HIV-1 RNA values >200 copies/mL on or after
week 16, with cases triggering virologic resistance testing. Resis-
tance testing was performed by Monogram Biosciences.
Statistical Analyses
ING116070 was a single-arm study to assess the distribution of
DTG into the CSF compartment. As such, it included no formal
hypothesis test. Pearson correlations between DTG concentra-
tions in plasma (total and unbound) and CSF at weeks 2 and 16
were calculated. Efficacy analyses were based on the intention-
to-treat exposed population. Subjects’ responses (eg, <50 copies/
mL) for plasma HIV-1 RNA were calculated and summarized
according to a missing, switch, or discontinuation equals failure
(MSDF) algorithm, as codified by the US Food and Drug Ad-
ministration Snapshot algorithm [23], wherein all subjects with-
out plasma HIV-1 RNA data at the visit of interest (eg, owing to
missing data or early discontinuation) or who changed their
concomitant ART (except for switches to permitted NRTIs be-
fore week 2) were treated as nonresponders. Otherwise, virolog-
ic success or failure for the visit of interest was determined by
the last available HIV-1 RNA assessment while the subject was
receiving treatment. Descriptive summaries were provided for
the following: absolute values and change from baseline in
HIV-1 RNA (plasma and CSF) and CD4+ cell counts; the inci-
dence and severity of all AEs, treatment-related AEs, AEs leading
to withdrawal, SAEs, and graded laboratory abnormalities; plasma
(total and unbound) and CSF (total) DTG concentrations; and
the incidence of PDVF or treatment-emergent genotypic and
phenotypic resistance to DTG and other on-study ART. The as-
sessments of DTG concentrations in plasma and CSF, and of CSF
HIV-1 RNA responses, were based on all available data.
RESULTS
Of 17 subjects screened, 13 subjects enrolled and received study
medication. All subjects were white men, 3 (23%) were of His-
panic ethnicity, and their median age was 42 years (range, 28–
52 years). Baseline characteristics are summarized in Table 1. At
the week 16 analysis, 2 subjects had prematurely withdrawn (1
before week 2 owing to a non–drug-related SAE of pharyngitis
and 1 owing to lack of treatment efficacy [ie, plasma HIV-1
RNA never suppressed to <200 copies/mL by week 16]). No
subjects had switched background NRTI therapy.
Evaluable, paired CSF and plasma pharmacokinetic samples
were available from 12 subjects at week 16; 1 subject at week 2
had pharmacokinetic samples collected outside the required
2–6 hour postdose sampling window, resulting in 11 evaluable
subjects at week 2. The DTG concentrations in CSF and plasma
are shown in Table 2. The median DTG concentrations in CSF
were 18 ng/mL (range, 4–23 ng/mL) at week 2 and 13 ng/mL
(4–18 ng/mL) at week 16, both of which exceeded the in vitro
50% inhibitory concentration (IC50) of 0.2 ng/mL. Concentrations
of DTG in CSF were low compared with plasma with median
CSF-plasma ratios of 0.52% (range, 0.12%–0.66%) at week
2 and 0.41% (range, 0.30%–2.04%) at week 16. The DTG
Table 1. Baseline Characteristics in the Intention-to-Treat
Exposed Population (N = 13)
Characteristic Results
Baseline plasma HIV-1 RNA
≤100 000 copies/mL, No. (%) 8 (62)
>100 000 copies/mL, No. (%) 5 (38)
Mean (SD), log10 copies/mL 4.93 (0.86)
Median (range), log10 copies/mL) 4.73 (3.60, 6.57)
Baseline CSF HIV-1 RNA
Mean (SD), log10 copies/mL 3.59 (1.21)
Median (range), log10 copies/mL 3.64 (1.46, 5.60)
Baseline CD4+ cell count
<350 cells/mm3, No. (%) 6 (46)
≥350 cells/mm3, No. (%) 7 (54)
Mean (SD), cells/mm3 409 (188)
Median (range), cells/mm3 360 (152, 863)
Nonreactive hepatitis B and C test results, No. (%)a 13 (100)
CDC category, No. (%)b
A 7 (54)
B 3 (23)
C 3 (23)
Abbreviations: CDC, US Centers for Disease Control and Prevention; CSF,
cerebrospinal fluid; HIV-1, human immunodeficiency virus type 1; SD,
standard deviation.
a Nonreactive results showed neither hepatitis B nor hepatitis C.
b CDC category A is defined as asymptomatic, lymphadenopathy, or acute HIV
infection; category B, symptomatic, not AIDS; and category C, AIDS.
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concentrations in CSF were similar to unbound plasma concen-
trations (Table 2). Ratios of DTG CSF total concentration to plas-
ma total concentration were similar to the unbound fractions of
DTG in plasma; these seemed to stay constant during the sam-
pling window and were similar between weeks 2 and 16.
At week 16, there was a significant correlation between total
DTG concentrations in CSF and plasma, as well as between total
DTG concentrations in CSF and unbound DTG concentrations
in plasma (Pearson correlation coefficient, 0.65 [P = .023] and
0.73 [P = .007], respectively).
CSF HIV-1 RNA levels decreased rapidly, with a median
change of −2.19 log10 copies/mL by week 2; 7 of 12 (58%)
and 11 of 12 (92%) subjects had CSF HIV-1 RNA levels <50
or <400 copies/mL, respectively, at week 2. By week 16, the me-
dian change from baseline in CSF HIV-1 RNA was −3.42 log10
copies/mL, which was similar to that observed in plasma
(−3.04 log10 copies/mL) at the same time point, although
there was no statistically significant correlation between the
two. In addition, DTG concentrations in CSF did not correlate
with changes from baseline in CSF HIV-1 RNA at week 16.
Results at week 16 showed that 10 (77%) and 12 (92%) of
13 subjects had plasma HIV-1 RNA levels <50 copies/mL or
<400 copies/mL, respectively, using the US Food and Drug
Administration Snapshot MSDF algorithm, and all 11 subjects
(100%) had CSF HIV-1 RNA levels below 50 copies/mL, using
all available data. Another subject had a late (day 141) assess-
ment for week 16 CSF HIV-1 RNA, which was <50 copies/
mL. Overall, at week 16, all subjects had CSF HIV RNA levels
<2 copies/mL, except 1 subject with a value of 5 copies/mL.
Eleven subjects had both plasma and CSF HIV-1 RNA data
available at week 16. Nine (82%) of them had HIV-1 RNA levels
<50 copies/mL in both plasma and CSF.
One subject met the definition of PDVF. This subject entered
the study with a plasmaHIV-1 RNA level of 6.57 log10 copies/mL,
which rapidly declined to 743 copies/mL by week 2, but never de-
creased to <200 copies/mL through week 16 (viral load, 236 cop-
ies/mL at week 16). No INI or major NRTI, nonnucleoside
reverse-transcriptase inhibitor or protease inhibitor mutations
were detected at the time of PDVF. Additionally, phenotypic anal-
yses showed susceptibility to all tested NRTIs, nonnucleoside re-
verse-transcriptase inhibitors, and protease inhibitor and no fold
change in susceptibility to either DTG or raltegravir (the first INI
approved for HIV treatment); the fold change in response to both
DTG and raltegravir was <1 at baseline.
At week 16, the median increase in CD4+ cell count was 226
cells/mm3 (interquartile range, 136–337 cells/mm3). Through the
week 16 analysis, no subject reported a new or recurrent Centers
for Disease Control and Prevention category B or C condition.
In general, DTG was well tolerated. Most AEs were grade 1 or
2 in intensity. Headache was the only AE reported by >2 sub-
jects (7 of 13 [54%]), with 2 headaches reported as being related
to the study drug. Headache is a known AE associated with
lumbar punctures, with the majority of such headaches reported
following the lumbar puncture.
Table 3 summarizes drug-related AEs reported in >1 subject;
all were considered grade 1 in intensity with the exception of a
single grade 2 worsening of depression that the investigator
thought might be related to the investigational product. The
subject had an extensive personal and family history of depres-
sion and was maintained in the study. No deaths occurred. One
subject prematurely withdrew from the study before week 2; this
was because of a grade 4, non–drug-related SAE of pharyngitis
and a grade 2 AE of syphilis. The only other SAE reported dur-
ing the study, in a different subject, was a non–drug-related SAE
of cholecystitis. No clinically significant trends in postdose lab-
oratory abnormalities were observed.
Table 2. Dolutegravir Concentrations in Plasma and Cerebrospinal Fluid
Dolutegravir Concentration
Week 2 (n = 12) Week 16 (n = 12)
Mean (SD) Median (Range) Mean (SD) Median (Range)
Plasma total, ng/mL 3420 (831) 3360 (2090–5280) 3030 (1350) 3210 (640–4920)
Plasma unbound, ng/mL 16.8 (4.10) 17.1 (10.3–24.0) 23.0 (8.24) 23.9 (3.81–32.1)
Unbound fraction in plasma, % 0.495 (0.082) 0.488 (0.333–0.655) 0.995 (1.05) 0.701 (0.488–4.30)
CSF total, ng/mL 16.2 (5.84)a 18.2 (4.0–23.2)a 12.6 (3.64) 13.2 (3.7–18.3)
CSF–total plasma ratio, % 0.467 (0.178)a 0.516 (0.115–0.658)a 0.546 (0.480) 0.412 (0.299–2.04)
Abbreviations: CSF, cerebrospinal fluid; SD, standard deviation.
a n = 11 (excluding 1 subject with pharmacokinetic samples collected outside the 2–6-hour postdose window).
Table 3. Most Common Drug-Related Adverse Eventsa
Type of Event Adverse Events, No. (%)
Any event 8 (62)
Fatigue 2 (15)
Headache 2 (15)
Nausea 2 (15)
a Adverse events reported for >1 subject in the safety population (N = 13).
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DISCUSSION
Many consider that distribution of antiretroviral drugs into
“sanctuary” sites in therapeutic concentrations favors suppres-
sion of HIV replication there. One such site, the CNS, may be
especially important because drug-resistant viruses that are not
present in blood have been found there (ie, the viruses can have
a different fold change in IC50 compared with those found in
the plasma [24]). In this study, DTG was measurable in all
CSF samples collected 2–6 hours after dosing and exceeded
the IC50 against wild-type virus (0.51 nmol/L = 0.2 ng/mL)
[25]. Median DTG CSF concentrations were 90-fold and 66-
fold above the IC50 at weeks 2 and 16, respectively, suggesting
that DTG achieves therapeutic concentrations in the CSF. The
planned narrow sampling window does not allow us to demon-
strate persistence of drug in the CSF over the entire dosing
interval, especially at the end of the interval when CSF concen-
trations might be lowest. However, DTG likely has slow clear-
ance of drug and flat concentration-time profiles in the CSF,
similar to what has been observed with other antiretrovirals
[26–28]. In addition, ABC and 3TC both distribute well into
the CNS [29, 30], indicating that a combination regimen of
ABC/3TC with DTG might be effective in rapidly clearing
HIV from the CSF. In parallel with these pharmacokinetic
data, HIV-1 RNA rapidly declined in both plasma and CSF,
and was undetectable (<50 copies/mL) at week 16 in the CSF
in all evaluable subjects and in plasma in 10 of 12 evaluable sub-
jects (83%), demonstrating the potent antiviral activity of this
regimen in multiple compartments.
Dolutegravir is highly protein bound in plasma, and only
total DTG was measured in the CSF owing to assay limits. How-
ever, the impact of protein binding for unbound DTG concen-
tration in the CSF is probably small because the concentration
of binding proteins (eg, albumin and α-1 acid glycoprotein) in
CSF is much lower than in plasma (100- to 1000-fold lower)
[31, 32]. This is supported by findings of other studies with
other highly bound antiretrovirals demonstrating that nearly
all the drug in the CSF was unbound [33]. The similarity of
the concentration of DTG in CSF and the unbound concentra-
tion in plasma implies that the distribution of DTG into CSF is
probably governed mainly by passive diffusion with a low pos-
sibility of active transporter involvement.
The more rapid decline in plasma HIV-1 RNA for an INI-
based versus an efavirenz-based regimen [34] makes the INI
class attractive for patients with high viral loads or with signifi-
cant issues, such as neurocognitive impairment. The distribu-
tion of raltegravir into CSF was evaluated in HIV-infected
patients [28]. Although raltegravir has a higher CSF-to-plasma
ratio of approximately 6% versus 0.5% for DTG, the greater
potency of DTG results in a much higher CSF inhibitory quo-
tient (ratio of drug concentration to IC50). The raltegravir
concentrations in CSF exceeded the IC50 for wild-type HIV
(3.2 ng/mL) in all specimens by a median of 4.5-fold, whereas
in this study DTG exceeded the IC50 by 66–90-fold. Although
the clinical relevance of these values is unknown, they suggest
the potential for a greater effect, especially if INI resistance is
present. Furthermore, DTG has demonstrated wild-type activity
against most INI single-mutant HIV-1 and thus provides a
greater barrier to the development of resistance in the CNS [25].
A previous phase IIa study (ING111521) has demonstrated
good correlation between DTG plasma concentration and reduc-
tion in HIV-1 RNA in plasma after 10-day monotherapy [35]. In
this current study, no correlation was identified between DTG
concentration in CSF and HIV-1 RNA reduction in CSF, primar-
ily because CSF concentrations were well in excess of the IC50 and
most subjects in the study had good responses to therapy in both
plasma and CSF. The uniformity of response did not allow for the
description of a concentration-effect relationship.
In general, DTG was well tolerated in the ART-naive, HIV-1–
infected subjects in this study. The most common AE was head-
ache, which was often temporally related to lumbar puncture and
not deemed related to study drug by the investigator in most
cases. Overall, the safety profile of DTG plus ABC/3TC in this
limited number of patients is consistent with findings of larger
phase III studies administering the same regimen [19, 20].
In 1 subject with PDVF, integrase genotypic or phenotypic re-
sults did not show development of resistance to INIs or NRTIs.
Other studies of DTG (50 mg once daily) in ART-naive patients
have demonstrated a lack of NRTI or INI resistance in partici-
pants with PDVF for up to 96 weeks of study, despite the devel-
opment of resistance in the comparator treatment arm [19, 20].
Given the pharmacokinetic and efficacy data in this study, the
combination of DTG, ABC, and 3TCmay be an effective regimen
in subjects with neurocognitive complications of HIV disease.
Notes
Acknowledgments. Thanks to ING116070 study participants, their
families and caregivers, the staff at each investigator site, and Katrina Oie
Rodenberger and Gina Uhlenbrauck for editorial assistance during the de-
velopment of the manuscript.
Disclaimer. The contents are the responsibility of the authors and do
not necessarily reflect the views of the funders.
Financial support. This work was supported by ViiV Healthcare.
Potential conflicts of interest. S. L. L. and K. T. T. received grant support
from ViiV Healthcare that supported their work on this study. S. L. L. has
grant support pending through institutions, including the National Insti-
tutes of Health (grants K24 MH097673, HHSN271201000036C), AbbVie,
Merck, and Gilead; has acted as a consultant for Merck; and has developed
educational presentations for which he has received payment for ViiV
Healthcare and AbbVie. K. T. T. has received grant support and has grant
support pending through institutions including Merck, Bristol-Myers
Squibb, and Gilead Sciences. A. M. M. has received grant support and hon-
oraria from ViiV Healthcare; has grant support pending through institu-
tions, including Gilead Sciences, Bristol-Myers Squibb, and AbbVie; and
has received fees for lectures from Gilead Sciences, including service on
1036 • CID 2014:59 (1 October) • HIV/AIDS
speakers bureaus. D. A. T., S. S. M., S. C., I. H. S., and S. C. P. are employees
of GlaxoSmithKline and own stock in the company.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Heaton RK, Clifford DB, Franklin DR Jr, et al; CHARTER Group.
HIV-associated neurocognitive disorders persist in the era of potent
antiretroviral therapy: CHARTER Study. Neurology 2010; 75:
2087–96.
2. Heaton RK, Franklin DR, Ellis RJ, et al; CHARTER and HNRC Groups.
HIV-associated neurocognitive disorders before and during the era of
combination antiretroviral therapy: differences in rates, nature, and pre-
dictors. J Neurovirol 2011; 17:3–16.
3. Spudich S, González-Scarano F. HIV-1-related central nervous system
disease: current issues in pathogenesis, diagnosis, and treatment. Cold
Spring Harb Perspect Med 2012; 2:a007120.
4. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between ce-
rebral spinal fluid and plasma HIV replication in patients with neuro-
logical symptoms who are receiving suppressive antiretroviral therapy.
Clin Infect Dis 2010; 50:773–8.
5. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal
fluid of subjects on suppressive antiretroviral treatment. J Infect Dis
2010; 202:1819–25.
6. Letendre S, Capparelli E, Best B, et al. Better antiretroviral penetration
into the central nervous system is associated with lower CSF viral load.
In: 13th Conference on Retroviruses and Opportunistic Infections, Den-
ver, Colorado, 5–8 February, 2006.
7. Letendre S, Marquie-Beck J, Capparelli E, et al; CHARTER Group.
Validation of the CNS penetration-effectiveness rank for quantifying
antiretroviral penetration into the central nervous system. Arch Neurol
2008; 65:65–70.
8. Cusini A, Vernazza PL, Yerly S, et al; the Swiss HIV Cohort
Study. Higher CNS penetration-effectiveness of long-term combination
antiretroviral therapy is associated with better HIV-1 viral suppression
in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62:
28–35.
9. Price RW, Spudich S. Antiretroviral therapy and central nervous system
HIV type 1 infection. J Infect Dis 2008; 197(suppl 3):S294–306.
10. Gisslen M, Hagberg L, Rosengren L, et al. Defining and evaluating HIV-
related neurodegenerative disease and its treatment targets: a combina-
torial approach to use of cerebrospinal fluid molecular biomarkers.
J Neuroimmune Pharmacol 2007; 2:112–9.
11. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on
immune activation reduces cerebrospinal fluid HIV-1 infection. J Ac-
quir Immune Defic Syndr 2008; 47:544–52.
12. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses
in neurological disorders: I. Establishment of reference values. Scand J
Clin Lab Invest 1977; 37:385–90.
13. Power C, Kong PA, Crawford TO, et al. Cerebral white matter changes
in acquired immunodeficiency syndrome dementia: alterations of the
blood-brain barrier. Ann Neurol 1993; 34:339–50.
14. Reichel A. The role of blood-brain barrier studies in the pharmaceutical
industry. Curr Drug Metab 2006; 7:183–203.
15. Isaac A, Taylor S, Cane P, et al. Lopinavir/ritonavir combined with
twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynam-
ics in blood, CSF and semen. J Antimicrob Chemother 2004; 54:
498–502.
16. Yilmaz A, Izadkhashti A, Price RW, et al. Darunavir concentrations in
cerebrospinal fluid and blood in HIV-1–infected individuals. AIDS Res
Hum Retroviruses 2009; 25:457–61.
17. Best BM, Koopmans PP, Letendre SL, et al; CHARTER Group. Efavir-
enz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob
Chemother 2011; 66:354–57.
18. Yilmaz A, Gisslén M, Sudich S, et al. Raltegravir cerebrospinal fluid con-
centrations in HIV-1 infection. PLoS One 2009; 4:e6877.
19. Raffi F, Jaeger H, Quiros-Roldan E, et al; extended SPRING-2 Study
Group. Once-daily dolutegravir versus twice-daily raltegravir in antire-
troviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week
results from a randomised, double-blind, non-inferiority trial. Lancet
Infect Dis 2013; 13:927–35.
20. Walmsley SL, Antela AA, Clumeck N, et al; SINGLE Investigators. Do-
lutegravir plus abacavir–lamivudine for the treatment of HIV-1 infec-
tion. N Engl J Med 2013; 369:1807–18.
21. Bennetto-Hood C, Tabolt G, Savina P, Acosta EA. A sensitive
HPLC-MS/MS method for the determination of dolutegravir in
human plasma. J Chromatog B Analyt Technol Biomed Life Sci 2014;
945–946:225–32.
22. Division of AIDS, National Institute of Allergy and Infectious Diseases.
Division of AIDS table for grading the severity of adult and pediatric
adverse events: version 1.0, December 2004; clarification August 2009.
Available at: http://rsc.tech-res.com/Document/safetyandpharma
covigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_
Events.pdf. Accessed 11 April 2014.
23. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the
FDA DAVP’s TLOVR algorithm in HIV submissions. Drug Inf J 2011;
45:291–300.
24. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid
(CSF)-penetrating antiretroviral drugs against HIV in the neurological
compartment: different patterns of phenotypic resistance in CSF and
plasma. Clin Infect Dis 2005; 41:1787–93.
25. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral proper-
ties of S/GSK1349572, a next-generation HIV integrase inhibitor. Anti-
microb Agents Chemother 2011; 55:813–21.
26. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA; HIV Neurobeha-
vioral Research Center Group. Indinavir population pharmacokinetics
in plasma and cerebrospinal fluid. Antimicrob Agents Chemother
2000; 44:2173–5.
27. Croteau D, Letendre S, Best BM, et al; CHARTER Group. Therapeutic
amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents
Chemother 2012; 56:1985–9.
28. Croteau D, Letendre S, Best BM, et al; CHARTER Group. Total ralte-
gravir concentrations in cerebrospinal fluid exceed the 50-percent in-
hibitory concentration for wild-type HIV-1. Antimicrob Agents
Chemother 2010; 54:5156–60.
29. Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA.
Population pharmacokinetics of abacavir in plasma and cerebrospinal
fluid. Antimicrob Agents Chemother 2005; 49:2504–6.
30. Foudraine NA, Hoetelmans RMW, Lange JMA, et al. Cerebrospinal-
fluid HIV-1 RNA and drug concentrations after treatment with lamivu-
dine plus zidovudine or stavudine. Lancet 1998; 351:1547–51.
31. Adam P, Sobek O, Táborský L, Hildebrand T, Tutterová O, Zácek P. CSF
and serum orosomucoid (α-1-acid glycoprotein) in patients with mul-
tiple sclerosis: a comparison among particular subgroups of MS pa-
tients. Clin Chim Acta 2003; 334:107–10.
32. Haas DW, Johnson B, Nicotera J, et al. Effects of ritonavir on indinavir
pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob
Agents Chemother 2003; 47:2131–7.
33. Croteau D, Rossi SS, Best BM, et al, CHARTER Group. Darunavir is
predominantly unbound to protein in cerebrospinal fluid and concen-
trations exceed the wild-type HIV-1 median 90% inhibitory concentra-
tion. J Antimicrob Chemother 2013; 68:684–9.
34. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir
(S/GSK1349572) in combination therapy in antiretroviral-naive
adults with HIV: planned interim 48 week results from SPRING-1, a
dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:
111–8.
35. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharma-
cokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy
in HIV-1-infected adults. AIDS 2011; 25:1737–45.
HIV/AIDS • CID 2014:59 (1 October) • 1037
